Journal of Comparative Effectiveness Research (May 2023)

Advanced or metastatic biliary tract cancer in Japan: a study using the Japan Medical Data Center payer claims database

  • Ramzi Argoubi,
  • Emily S Reese,
  • Martina Furegato,
  • Patricia Medina,
  • Sarah Bobiak

DOI
https://doi.org/10.57264/cer-2022-0201
Journal volume & issue
Vol. 12, no. 6

Abstract

Read online

Aim: Biliary tract cancers are aggressive, with poor prognosis. This study describes clinical characteristics, treatment patterns and healthcare resource utilization in patients with metastatic biliary tract cancer in Japan. Materials & methods: This cohort-based study collected data from the Japan Medical Data Center claims database (2014–2018). Results: A total of 325 patients were included; 65.2% were male and the mean age was 59.2 years. A 47.6% had an Elixhauser Comorbidity Index score ≥5. Most frequent regimens were gemcitabine + cisplatin (52.9%) for first-line therapy and tegafur + gimeracil + oteracil for secondline therapy (48.6%) and third-line therapy (27.2%). Approximately 77% of patients had ≥1 hospital admission, with a median length of 57 days. Conclusion: This study provides insights on the characteristics and burden of metastatic biliary tract cancer in Japan, highlighting high disease burden in a younger population.

Keywords